-
Mianserin HCl: From Receptors to Translation
2026-09-22
Mianserin HCl is more than a 5-HT2 receptor antagonist: it is a translational antidepressant research compound linking receptor pharmacology, plasma exposure, formulation, and antipathogenic hypotheses. This article explains how to interpret those evidence streams without confusing assay activity with clinical proof.
-
Monomeric Aβ and Microglial Inflammation in the Brain
2026-09-22
This preprint identifies an APP and heterotrimeric G protein pathway through which monomeric amyloid-β suppresses inflammatory activity in brain microglia. Its findings connect microglial regulation with cortical development and provide a mechanistic framework for interpreting how amyloid-β molecular state may influence Alzheimer's disease biology.
-
Amyloid Beta-Peptide (1-40): Calcium-Aware Assays
2026-09-21
Amyloid Beta-Peptide (1-40) (human) enables calcium-aware studies of membrane binding, aggregation, and neurotoxicity. This guide translates supercritical-angle spectroscopy findings into practical decisions for Alzheimer's disease research assays.
-
Deuterium-Labeled Degarelix: Synthesis and Significance
2026-09-21
The reference study describes a practical 13-step synthesis of deuterium-labeled degarelix acetate, using early D2O/D3PO4-mediated labeling of a naphthyl amino acid before Fmoc-based peptide assembly. Its main contribution is a usable isotopologue route that produced an internal standard for future degarelix absorption, distribution, metabolism, and excretion studies.
-
Aβ42 Beyond Plaques: Designing Translational Models
2026-09-20
A mechanistic guide to using Amyloid β-Peptide (1-42) in Alzheimer’s disease research, linking aggregation state, microglial phagocytosis, neuronal toxicity, and ion-channel biology to more predictive translational workflows.
-
FPS-ZM1: A Practical RAGE Inhibitor Workflow
2026-09-19
Use FPS-ZM1 as a selective mechanistic probe to separate RAGE-driven effects from broader metabolic or anti-inflammatory actions. This workflow connects hypothalamic RAGE/POMC studies with amyloid beta transport, neuronal stress, and neuroinflammation assays while keeping preclinical evidence and clinical expectations distinct.
-
CNO and Circuit Precision in Translational Neuroscience
2026-09-18
Clozapine N-oxide is more than a DREADDs activator: it is a strategic tool for testing how defined inhibitory microcircuits shape stress-related behavior. This article connects CNO-enabled neuronal activity modulation with basolateral amygdala biology, experimental controls, translational maturity, and reproducible workflow design.
-
GOB-38 in Elizabethkingia anophelis: Study Insights
2026-09-18
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that its substrate profile spans penicillins, cephalosporins, and carbapenems. Its combination of recombinant enzyme analysis, comparative genomics, and co-culture experiments clarifies how this enzyme may contribute to β-lactam resistance and highlights the need for substrate-specific validation.
-
Nanoparticle Uptake in Human Corneal Epithelial Cells
2026-09-17
Azadi and David developed a controlled PLGA nanoparticle platform to determine how particle size and surface chemistry affect uptake by human corneal epithelial cells. Their results identify energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, as the dominant mechanisms under the tested conditions and provide design guidance for topical ocular delivery.
-
Caffeic Acid Phenethyl Ester for NF-κB Assays
2026-09-17
CAPE is a practical NF-κB pathway probe for connecting inflammatory signaling with angiogenesis, invasion, and neurodegeneration workflows. Its strongest use is as one component of a controlled assay panel that combines pathway, viability, cytokine, and disease-relevant phenotypes.
-
FPS-ZM1: From RAGE Target to Causal Assay
2026-09-16
FPS-ZM1 is a selective RAGE inhibitor for dissecting amyloid beta signaling, neuroinflammation, and emerging RAGE/POMC biology. This article translates recent berberine research into a rigorous assay strategy while separating established evidence from testable hypotheses.
-
Nilotinib (AMN-107): From BCR-ABL to Brain Biology
2026-09-16
Nilotinib (AMN-107) is best understood as a selective kinase probe with a strong BCR-ABL foundation and a broader translational reach across KIT, PDGFR, and c-Abl biology. This article connects chronic myeloid leukemia research with a carefully bounded neurodegeneration study, showing how mechanistic specificity, model selection, and disciplined interpretation can improve kinase-driven research.
-
How CaCl2 Shapes Amyloid-β Aggregation
2026-09-15
The reference study uses supercritical-angle Raman and fluorescence spectroscopy and microscopy to resolve calcium-dependent amyloid-β behavior at lipid-membrane surfaces. Its central finding is that a calcium-associated interfacial layer can reduce membrane insertion, while the effect depends on peptide isoform and whether aggregation has already begun.
-
H-89 in Wnt–PKA Bone Metabolism Assays
2026-09-15
H-89 is a cAMP-dependent protein kinase inhibitor that can help resolve how Wnt signaling connects PKA activity with O-GlcNAcylation, glycolysis, and osteoblast formation. This article presents a time-resolved assay strategy that distinguishes pathway causality from nonspecific cellular effects.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-14
Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib sensitivity in malignant pleural mesothelioma models, with particular relevance to BAP1-mutated cells. Their work supports molecular stratification of mesothelioma chemotherapy research while highlighting the limitations of translating in vitro PARP-inhibitor responses into clinical treatment decisions.